Caris Life Sciences and Flare Therapeutics have announced a partnership to advance the precision oncology pipeline of the latter into clinical trials. The multi-year strategic partnership will leverage latest molecular profiling approaches guiding patient selection and participation to accelerate precision medicine approaches across five of the therapeutic programmes of Flare. It will use the comprehensive molecular tissue and liquid profiling services of Caris including whole transcriptome sequencing and whole exome sequencing for participants in Flare’s clinical trials. Additionally, the partnership will apply Caris’ data and analytics tools to strengthen future enrolment programme for trials and companion diagnostics capabilities. Flare Therapeutics chief development officer Michaela Bowden said: “We understand the importance of shaping translational insights early on as a major area of focus to help ensure efficient drug development at scale and clinical trial preparedness. “With access to Caris’ robust clinico-genomic real-world data, comprehensive molecular profiling and ...
Medicare Advantage, the private-sector alternative to original Medicare, now enrolls nearly half of all Medicare beneficiaries. But it remains controversial because — while most of its subscribers like the extra benefits many plans provide — the program frequently costs the federal government more than if those seniors remained in the fully public program. That controversy is becoming political, as the Biden administration tries to rein in some of those payments without being accused of “cutting” Medicare. Meanwhile, President Joe Biden has signed a bill to declassify U.S. intelligence about the possible origin of covid-19 in China. And new evidence has emerged potentially linking the virus to raccoon dogs at an animal market in Wuhan, where the virus reportedly first took hold. Among the takeaways from this week’s episode: The Biden administration recently changed the formula used to calculate how much the federal government pays private Medicare Advantage ...
In a recent study published in the JAMA Health Forum, researchers in the United States estimated the reduction in coronavirus disease 2019 (COVID-19) mortality rates after the Paxlovid rollout. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections were the third largest cause of mortality in the United States in 2022, and after the Food and Drug Administration (FDA) approved Paxlovid (nirmatrelvir and ritonavir), the test-to-treat strategy became a pillar of the US pandemic response. Treatment with Paxlovid necessitates testing and medication initiation within five days after COVID-19 symptoms start. However, the population-level effect of the Paxlovid rollout has not been evaluated. About the study In the present study, researchers estimated the simulated influence of the Paxlovid rollout on COVID-19-related hospitalizations and deaths. The team modeled COVID-19-related hospitalization and death rate reductions after Paxlovid introduction as the product of (1) the number of symptomatic patients diagnosed within five ...
Infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is the causal agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, has claimed more than 6.8 million lives worldwide. It remains imperative to understand the immune responses to SARS-CoV-2, particularly in high-risk groups, to formulate better vaccination and treatment strategies. The immune response to COVID-19 during pregnancy Immunological assessment related to COVID-19 has been performed largely in healthy individuals across varied age groups. After contracting SARS-CoV-2 infection, patients typically develop robust and transient immune responses that include an abundance of SARS-CoV-2-specific antibodies, T-cells, B-cells, and long-lasting immune memory. Severe SARS-CoV-2 infection has been characterized by the presence of blood hypercytokinemia and hyperactivation of innate/adaptive immune responses. Limited studies have been performed on the immune response after SARS-CoV-2 infection in pregnant women. Pregnant women are considered to be highly susceptible to COVID-19 due to immunological and physiological changes ...
Although smoking rates for adults in the US are at their lowest recorded levels, more must be done to stop children from using tobacco, according to a new set of policy statements from the American Academy of Pediatrics. The statements, published Monday, are the association’s first tobacco policy update since 2015. They’re based on newer science and better reflect how many children now use e-cigarettes as more kid-friendly products have flooded the market. AAP policy statements are created by expert pediatricians to help leaders craft more effective public health policy and to guide physicians on how to keep kids safe – in this case, from tobacco. High rates of tobacco use Researchers have been telling Americans for generations that tobacco products are bad for them, yet nearly 200 US children take up smoking every day, according to the US Centers for Disease Control and Prevention. Tobacco ...
The Epstein-Barr virus (EBV) is easily spread through bodily fluids, primarily saliva, such as kissing, shared drinks or using the same eating utensils. Not surprisingly then, EBV is also among the most ubiquitous of viruses: More than 90% of the world’s population has been infected, usually during childhood. EBV causes infectious mononucleosis and similar ailments, though often there are no symptoms. Most infections are mild and pass, but the virus persists in the body, becoming latent or inactive, sometimes reactivating. Long-term latent infections are associated with several chronic inflammatory conditions and multiple cancers. In a new paper, published April 12, 2023 in the journal Nature, researchers at University of California San Diego, UC San Diego Moores Cancer Center and Ludwig Cancer Research at UC San Diego, describe for the first time how the virus exploits genomic weaknesses to cause cancer while reducing the body’s ability to suppress it. These findings show ...
Before undergoing surgeries and other invasive medical procedures, patients typically undergo anesthesia. Anesthesia consists in giving patients a class of drugs (i.e., anesthetics) that cause them to lose feeling in specific areas of the body (i.e., local anesthesia) or fully lose awareness during a procedure (i.e., general anesthesia). These anesthetics can be administered to patients via injection, inhalation, skin-numbing lotions, and other means. In the past, doctors and medical researchers viewed general anesthesia as a passive process that could not be influenced or interrupted once anesthetic drugs were administered. More recently, however, studies showed that it is in fact an active brain process that can be experimentally controlled and acted on. A research team at the Southern University of Science and Technology in China recently carried out a study investigating the processes underpinning brain states while under general anesthesia and those associated with the subsequent re-emergence of awareness. Their findings, published in Nature Neuroscience, highlight possible strategies that could help anesthesiologists to extend ...
A stop-smoking mobile app that senses where and when you might be triggered to light up could help you quit, according to University of East Anglia research. Quit Sense is the world’s first Artificial Intelligence (AI) stop smoking app that detects when people are entering a location where they used to smoke. It then provides support to help manage people’s specific smoking triggers in that location. A study published today shows how the new app helped more smokers to quit than people who were only offered online NHS support. The research team hopes that by helping people manage trigger situations, the new app will help more smokers to quit. The work is published in Nicotine and Tobacco Research. Lead researcher Prof Felix Naughton, from UEA’s School of Health Sciences, said, “We know that quit attempts often fail because urges to smoke are triggered by spending time ...
More than 2.5 million cases of sexually transmitted infections were reported in 2021, jumping by 7% in one year, according to new data from the US Centers for Disease Control and Prevention. “The US STI epidemic shows no signs of slowing,” said Dr. Leandro Mena, director of the CDC’s Division of STD Prevention. Chlamydia accounted for more than half of the reported cases, with rates increasing about 4% in 2021. Cases of gonorrhea rose nearly 5%. Cases of syphilis surged 32% in one year, including an alarming rise in infections passed from pregnant mothers to babies developing in the womb. In 2021, congenital syphilis caused 220 stillbirths and infant deaths. “The most important thing to remember is that congenital syphilis is 100% preventable,” Mena said. “In many ways, it is the result of our failure to prevent syphilis among women of reproductive age and their partners.” ...
After decades under Johnson & Johnson, a massive plant that once cranked out over-the-counter mainstays like Pepcid and Imodium is poised to hit the market. The plant handover comes after last month’s news that Johnson & Johnson would cut 57 positions at the Lancaster County facility, as detailed in a local Worker Adjustment and Retraining Notification Act notice. High Properties acquired J&J’s Greenfield, Pennsylvania, consumer health facility for $14 million, local news outlet Lancaster Online first reported. Fierce Pharma has viewed a copy of the deed confirming the sale, which went through in late March. J&J and High Properties did not immediately respond to Fierce Pharma’s request for comment on the matter. Reference: https://deal.town/questex/041223-takeda-hit-with-another-pay-for-delay-lawsuit-after-layoff-warning-jandj-inks-14m-plant-sale-F34YGQUSL
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.